There are currently 632 clinical trials in Louisville, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Louisville, Jewish Hospital, Norton Cancer Institute and Saints Mary and Elizabeth Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab together with ustekinumab in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Crohn's Disease
Register for Updates
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06230523
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 13 visits.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/20/2024
Locations: L-MARC Research Center, Louisville, Kentucky
Conditions: Obesity, Overweight and Obesity
Register for Updates
Transcutaneous Spinal Stimulation: Safety and Feasibility for Upper Limb Function in Children With Spinal Cord Injury
NCT04032990
Recruiting
Children who suffer a spinal cord injury in the neck region have difficulty using their hands due to paralysis and/or weakness of their arms and hand muscles. The purpose of this project is to test the safety, comfort, and practicality of a new therapy that stimulates the spinal cord to facilitate activation of arm and hand muscles while practicing grasping, pinching, and reaching movements. The long-term goal is to provide better therapies that will improve the ability of children with SCI to m... Read More
Gender:
All
Ages:
Between 4 years and 18 years
Trial Updated:
06/20/2024
Locations: Department of Neurosurgery, Louisville, Kentucky
Conditions: Spinal Cord Injuries
Register for Updates
Neonatal Phase 1 Valacyclovir Study
NCT05468619
Recruiting
A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration.... Read More
Gender:
All
Ages:
Between 1 day and 2 days
Trial Updated:
06/20/2024
Locations: University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky
Conditions: Herpes Simplex
Register for Updates
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
NCT06153693
Recruiting
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky
Conditions: Hypertension
Register for Updates
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky +1 locations
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Register for Updates
CERENOVUS Neurothrombectomy Devices Registry
NCT03685578
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC™ Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter in acute ischemic stroke patients with confirmed intracranial vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Norton Healthcare, Louisville, Kentucky
Conditions: Cerebral Stroke
Register for Updates
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
NCT03373045
Recruiting
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based survey... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/20/2024
Locations: Research Site, Louisville, Kentucky
Conditions: Asthma
Register for Updates
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902
Recruiting
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Jewish Hospital, Louisville, Kentucky +2 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
NCT04796337
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Norton Pulmonary Specialists ( Site 1066), Louisville, Kentucky
Conditions: PAH, Pulmonary Arterial Hypertension
Register for Updates
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT04557735
Recruiting
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.
Gender:
All
Ages:
17 years and below
Trial Updated:
06/20/2024
Locations: Research Site, Louisville, Kentucky
Conditions: Thrombotic Microangiopathy
Register for Updates
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: University of Louisville Healthcare Outpatient Research Clinic, Louisville, Kentucky
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates